Journal article
Predicting the need for third-line antiretroviral therapy by identifying patients at high risk for failing second-line antiretroviral therapy in South Africa
- Abstract:
- Although third-line antiretroviral therapy (ART) is available in South Africa’s public sector, its cost is substantially higher than first and second line. Identifying risk factors for failure on second-line treatment remains crucial to reduce the need for third-line drugs. We conducted a case–control study including 194 adult patients (‡18 years; 70 cases and 124 controls) who initiated second-line ART in Johannesburg, South Africa. Unconditional logistic regression was used to assess predictors of virologic failure (defined as 2 consecutive viral load measures ‡1000 copies/mL, ‡3months after switching to second line). Variables included a social instability index, ART adherence, self-reported as well as diagnosed adverse drug reactions (ADRs), HIV disclosure, depression, and factors affecting access to HIV clinics. Overall 60.0% of cases and 54.0% of controls were female. Mean ages of cases and controls were 41.8 – 9.6 and 43.3 – 8.0, respectively. Virologic failure was predicted by ART adherence <90% [odds ratio (OR) 4.7; 95% confidence interval (95% CI): 2.1–10.5], younger age (<40 years of age; OR 0.6; 95% CI: 0.3–1.1), high social instability (OR 3.8; 95% CI: 1.30–11.5), self-reported ADR (OR 1.9; 95% CI: 1.0–3.5), disclosure to friends/colleagues rather than partner/relatives (OR3.4; 95%CI: 1.3–9.1), andmedium/high depression compared to low/no depression (OR 4.4; 95% CI: 1.5–13.4). Our results suggest complex socioeconomic factors contributing to risk of virologic failure, possibly by impacting ART adherence, among patients on second-line therapy in South Africa. Identifying patients with possible indicators of nonadherence could facilitate targeted interventions to reduce the risk of second-line treatment failure and mitigate the demand for third-line regimens.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 135.4KB, Terms of use)
-
- Publisher copy:
- 10.1089/apc.2016.0291
Authors
- Publisher:
- Mary Ann Liebert publishers
- Journal:
- AIDS Patient Care and STDs More from this journal
- Volume:
- 31
- Issue:
- 5
- Pages:
- 205-212
- Publication date:
- 2017-05-01
- DOI:
- EISSN:
-
1557-7449
- ISSN:
-
1087-2914
- Keywords:
- Pubs id:
-
pubs:853641
- UUID:
-
uuid:e1ced5b6-d036-42f0-af92-dd7527b11392
- Local pid:
-
pubs:853641
- Source identifiers:
-
853641
- Deposit date:
-
2018-06-22
Terms of use
- Copyright holder:
- Onoya et al
- Copyright date:
- 2017
- Notes:
- © Dorina Onoya, et al., 2017; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
If you are the owner of this record, you can report an update to it here: Report update to this record